Target General Information
Target ID	T53472
Target Name	Killer cell immunoglobulin-like receptor 2DL3
Synonyms	CD158 antigenlike family member B2; CD158b2; KIR023GB; Killer inhibitory receptor cl 23; MHC class I NK cell receptor; NKAT2; NKAT2a; NKAT2b; Natural killerassociated transcript 2; p58 NK receptor CL6; p58 natural killer cell receptor clone CL6; p58.2 MHC classIspecific NK receptor; KIR2DL3
Target Type	Clinical Trial
Gene Name	KIR2DL3
Biochemical Class	Immunoglobulin
UniProt ID	KI2L3_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease	Acute myelocytic leukemia
Example drug	IPH-2102			Phase 2	[524057], [1572592]
Tissue	Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual	Fold-change: -0.30 Z-score: -0.61 P-value: 3.74E-13
Target gene expression profiles of the patients in the disease section of the tissue Target gene expression profiles in the tissue of healthy individual Download target gene expression data of the patients in the disease section of the tissue Download target gene expression data in the tissue of healthy individual
Disease	Myeloma
Example drug	mab 1-7F9			Phase 2	[530228], [530238], [1572592]
Tissue	Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual	Fold-change: -0.32 Z-score: -2.19 P-value: 5.34E-04
Target gene expression profiles of the patients in the disease section of the tissue Target gene expression profiles in the tissue of healthy individual Download target gene expression data of the patients in the disease section of the tissue Download target gene expression data in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Download the Expression Profile (Genomics. 86(2):127-41, 2005)
Reference
Ref 530228	Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009 Sep 24;114(13):2667-77.
Ref 530238	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
Ref 524057	ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
Ref 1572592	NCBI GEO: archive for functional genomics data sets--update.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.